Coastlands Capital LP bought $33k of ADIL
owner at ADIAL PHARMACEUTICALS, INC.. 11,753 shares at an average of $2.78, traded Jul 9, 2026, filed Jul 13, 2026.
Score components
- +12Role10% owner
- +6Trade size$33k at market
- 0Relative to holdingsHoldings up 3.1%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-082972, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 9, 2026 | POpen-market purchase Common Stockindirect: By Coastlands Capital LP | +10,053 | $2.79 | $28k | 383,375 | Jul 13, 2026 |
| Jul 10, 2026 | POpen-market purchase Common Stockindirect: By Coastlands Capital LP | +1,700 | $2.70 | $4,590 | 385,075 | Jul 13, 2026 |
Related signals
Other insiders at ADIAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 7Weak | ADILbuy ADIAL PHARMACEUTICALS, INC. | Coastlands Capital LP owner | $8,691 3,233 shares | +1% | |
| 18Weak | ADILbuy ADIAL PHARMACEUTICALS, INC. | Coastlands Capital LP owner | $65k 25,000 shares | +7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.